Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial
JL Ritchie,
M Cerqueira,
C Maynard,
K Davis,
and
JW Kennedy
Department of Medicine, Veterans Administration Medical Center, Seattle, Washington.
The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Trial randomized 368 patients with symptoms and signs of acute myocardial infarction of less than 6 h duration to either conventional care or 1.5 million units of intravenous streptokinase. The mean time to randomization was 209 min and 52% of patients were randomized within 3 h of symptom onset. Quantitative, tomographic thallium-201 infarct size and radionuclide ejection fraction were measured at 8.2 +/- 7.5 weeks in 207 survivors who lived within a 100 mile radius of a centralized laboratory. Overall, infarct size as a percent of the left ventricle was 19 +/- 13% for control subjects and 15 +/- 13% for treatment patients (p = 0.03). For anterior infarction in patients entered within 3 h of symptom onset, infarct size was 28 +/- 13% in the control group versus 19 +/- 15% for the treatment group (p = 0.09). Left ventricular ejection fraction was 47 +/- 15% in the control versus 51 +/- 15% in the treatment group (p = 0.08). For anterior infarction of less than 3 h duration, the ejection fraction was 38 +/- 16% in the control versus 48 +/- 20% in the treatment group (p = 0.13). By statistical analysis incorporating the nonsurvivors, p values for all of these variables were less than or equal to 0.08. There was no benefit for patients with inferior infarction or for anterior infarction of greater than 3 h duration. It is concluded that intravenous streptokinase, when given within 3 h of symptom onset to patients with anterior infarction, reduces infarct size and improves ventricular function.
This article has been cited by other articles:
|
|
|
|
 
A. Schomig, G. Ndrepepa, and A. Kastrati
Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction
Eur. Heart J.,
August 2, 2006;
27(16):
1900 - 1907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Davis, C. O'Sullivan, P. H. Jarritt, and J. B. Porter
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
Blood,
July 1, 2004;
104(1):
263 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Chareonthaitawee, R J Gibbons, R S Roberts, T F Christian, and R Burns
The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction
Heart,
August 1, 2000;
84(2):
142 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Christian, I. P. Clements, T. Behrenbeck, K. C. Huber, J. H. Chesebro, B. J. Gersh, and R. J. Gibbons
Limitations of the Electrocardiogram in Estimating Infarction Size after Acute Reperfusion Therapy for Myocardial Infarction
Ann Intern Med,
February 15, 1991;
114(4):
264 - 270.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. W. Sharkey, D. D. Brunette, E. Ruiz, W. T. Hession, D. G. Wysham, I. F. Goldenberg, and M. Hodges
An Analysis of Time Delays Preceding Thrombolysis for Acute Myocardial Infarction
JAMA,
December 8, 1989;
262(22):
3171 - 3174.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. J. Tiefenbrunn and P. A. Ludbrook
Coronary Thrombolysis-- It's Worth the Risk
JAMA,
April 14, 1989;
261(14):
2107 - 2108.
[Abstract]
[PDF]
|
|
|
|
